Skip to main content
Premium Trial:

Request an Annual Quote

Robert Hershberg

NanoString Technologies announced that Robert Hershberg has joined its board of directors as of March 2, bringing the total number of members to six.

Hershberg in July 2014 became VP of immuno-oncology at Celgene Corporation. He leads Celgene's early R&D efforts in that space and is in charge of the new Celgene Immuno-Oncology Center of Excellence in Seattle, Washington. Hershberg also founded and is CEO of VentiRx Pharmaceuticals and is an independent member of the board of directors for Adaptive Biotechnologies Corporation. 

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.